Back

A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - treatment 2 Treatment HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Elisabetta Salvioni

Monzino Cardiology Centre, Milan (Italy)

6 More presentations in this session

Presentation thumbnail
Evaluating the efficacy and safety of beta-3 adrenergic receptor agonists in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials
Mr L. Rezende De Freitas (BR)
Abstract Slides Video
Presentation thumbnail
Assessment of remote patient monitoring in patients with chronic heart failure across four European sites
Ms M. Verket (Aachen, DE)
Abstract Slides Video
Presentation thumbnail
Exploring the relationship between EuroSCORE II and aortic calcification in predicting clinical outcomes following cardiac surgery
Ms A. Pacheco (Aveiro, PT)
Abstract Slides Video
Presentation thumbnail
Assessment of treatment adherence in patients with chronic heart failure using the 8-item Morisky Medication Adherence Scale (MMAS-8)
Doctor A. Baigozhina (Astana, KZ)
Abstract Slides Video
Presentation thumbnail
Sodium reduction with low-sodium umami-flavoured bread in chronic heart failure: a randomized clinical pilot study.
Doctor F. Gommans (Veldhoven, NL)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - treatment 2

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation
thumbnail
Congress Presentation
Navigating the realms of SGLT2 inhibitors bridging clinical studies enthusiasm with practical realities
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources